Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment save search
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalLack of early symptom improvement is not predictive of final responder status
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
STIM | $3.76 -2.59% -2.66% 21K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Published: 2024-04-10 (Crawled : 20:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: 0.72%
H: 1.6%
C: -0.36%
metabolic treatment for
Soil Treatment Market size is set to grow by USD 16.46 billion from 2023-2027, Need to meet rising demand for crops boost the market, Technavio
Published: 2024-04-10 (Crawled : 13:30) - prnewswire.com
CODYY | $15.08 -0.13% 1.6M
|
Manufacturing
|
| O: -3.01%
H: 1.44%
C: 0.84%
treatment for set market
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
STIM | $3.76 -2.59% -2.66% 21K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
CMND | $1.19 -1.65% -1.68% 26K
|
n/a
|
| O: -3.03%
H: 7.03%
C: -0.78%
patent disorders treatment for application
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy on May 23, 2024
Published: 2024-04-10 (Crawled : 11:00) - biospace.com/
TBPH | $9.16 -0.65% -0.66% 300K
|
Health Technology
|
| O: -1.37%
H: 2.14%
C: 2.03%
treatment system for key potential
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Published: 2024-04-10 (Crawled : 10:00) - prnewswire.com
TBPH | $9.16 -0.65% -0.66% 300K
|
Health Technology
|
| O: -1.37%
H: 2.14%
C: 2.03%
treatment system for key potential
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.505 1.01% 1.0% 1.9M
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
Published: 2024-04-09 (Crawled : 13:00) - globenewswire.com
PRFX 4 d | $0.841 -5.48% -5.8% 23K
|
Health Technology
|
| O: 15.88%
H: 29.44%
C: -23.35%
treatment for
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
TENX | $3.51 0.29% 0.28% 7.9K
|
Health Technology
|
| O: 7.89%
H: 1.95%
C: -2.93%
first levosimendan treatment ongoing for therapeutics potential
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
LSTA | $2.79 5.28% 5.02% 9.6K
|
Manufacturing
|
| O: 0.34%
H: 9.62%
C: 3.78%
fda drug granted treatment designation for therapeutics
Jacobs to Design Miami-Dade Wastewater Treatment Plant Expansion and Upgrades
Published: 2024-04-09 (Crawled : 12:00) - prnewswire.com
J | $143.98 -0.45% -0.71% 350K
|
Industrial Services
|
| O: -0.99%
H: 0.22%
C: -0.14%
ACM | $94.01 0.14% -0.96% 580K
|
Industrial Services
|
| O: 0.24%
H: 0.18%
C: -1.91%
treatment expansion design
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MDGL | $204.51 -6.35% -6.78% 580K
|
Health Technology
|
| O: 2.12%
H: 0.7%
C: -0.82%
liver treatment fibrosis pharmaceuticals for advanced nash
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
SYRS | $5.055 -1.65% -1.68% 90K
|
Health Technology
|
| O: 2.16%
H: 23.21%
C: 16.03%
fda treatment designation for aml
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
NRXP 5 d | $3.11 1.97% 1.93% 96K
|
Manufacturing
|
| O: 0.57%
H: 7.01%
C: 3.79%
nrx-101 depression treatment pharmaceuticals trial
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
INMB | News 0 d | $10.605 4.59% 4.38% 110K
|
Health Technology
|
| O: 0.97%
H: 3.96%
C: 0.0%
inb03 breast cancer treatment
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | News 0 d | $12.0 0.25% 0.25% 190K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Published: 2024-04-08 (Crawled : 09:00) - biospace.com/
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -1.06%
H: 3.5%
C: 0.51%
patent cancer treatment for application
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.